Skip to content

Retinal Imaging Using NOTAL-OCT V3.0

Retinal Imaging Using NOTAL-OCT V3.0

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04078672
Enrollment
58
Registered
2019-09-06
Start date
2019-12-02
Completion date
2023-03-26
Last updated
2023-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AMD, DR

Brief summary

The study will include up to 250 AMD patients and up to 30 DR patients. In Tel Aviv medical center up to 100 AMD/ 20 DR patients will be recruited; In Assuta HaShalom up to 100 AMD/10 DR patients will be recruited; In Bnei Zion medical center up to 50 AMD patients will be recruited. 4.1 Study population 1. AMD patients - intermediate and advanced AMD (with active or non-active CNV) 2. DR patients - with and without edema 4.2 Inclusion criteria 1. Ability and agreement to give informed consent (IC) 2. Diagnosis of AMD or DR in SE by OCT 3. Ability to undergo OCT scans 4. VA of 20/400 (6/120) or better in study eye(s) 4.3 Exclusion criteria 1\. Patient with dilated eye(s)

Detailed description

4.5.1 SCREENING VISIT: For patients eligible to participate in the study, the following procedure will be done in the screening visit: 1. Patient will sign the IC (Informed Consent) form 2. Test the eligible eye(s) of the patient will be tested 3. The following demographic and clinical data will be collected for each tested eye and will be registered in the CRF: 1. Patient's DOB and gender. 2. Patient's diagnosis in study eye(s), based on patient's medical record, including media opacity (e.g. cataract or corneal opacity, if exists). 3. Examination to check habitual correction, pinhole VA and refraction. 4.5.2 OCT Visit 1: may take place on the same day as screening visit. For each eligible eye, testing will include: d. Refraction by auto-refractometer e. Commercial OCT scanning: i. Scanning pattern: Macular cube of at least 6mm (20 degrees); At least 40 B-scans per cube f. NOTAL-OCT V3.0 scanning: i. Scanning pattern Macular cube of the central 10 degrees of the macula At least 40 B-scans per cube ii. The patients will undergo an interactive tutorial that will teach the patient to self-operate the NOTAL-OCT V3.0 device. The tutorial will be done only once, using the eye with the better VA. iii. To check repeatability, image capturing phase will include up to 8 testing sessions, each \ 2 minutes long. iv. Patients will rest for 5 minutes between sessions. v. Total examination time with NOTAL-OCT V3.0 is expected to be less than an hour. vi. In case of patient's fatigue during the testing procedure, examination session will be terminated. vii. The study staff will administer the NOTAL-OCT V3.0 patient-experience questionnaire at the 1st OCT Visit. 4.5.3 OCT Visits 2-6: For each eligible eye, imaging will include: a. Commercial OCT scanning: i. Scanning pattern: Macular cube of at least 6mm (20 degrees); At least 40 B-scans per cube b. NOTAL-OCT V3.0 scanning: i. Scanning pattern Macular cube of the central 10 degrees of the macula At least 40 B-scans per cube ii. Image capturing phase that will include up to 8 testing sessions, each a\ 2 minutes long. iii. Patients will rest for 5 minutes between sessions. iv. Total examination time with the NOTAL-OCT V3.0 is expected to be less than an hour. v. In case of patient's fatigue during the testing procedure, examination will be terminated. c. VA of eye(s) participating in the study. d. Clinical diagnosis of eye(s) participating in the study.

Interventions

PROCEDURENOTAL-OCT V3.0

AMD and DR patients

Sponsors

Notal Vision Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 1\. Ability and agreement to give informed consent (IC) 2. Diagnosis of AMD or DR in SE by OCT 3. Ability to undergo OCT scans 4. VA of 20/400 (6/120) or better in study eye(s)

Exclusion criteria

* 1\. Patient with dilated eye(s)

Design outcomes

Primary

MeasureTime frameDescription
To evaluate the level of agreement between OCT images captured by NOTAL-OCT V3.0 and by a commercial OCTLess then an hourThe measurement of fluid as identified by an eye-care professional, in the central 10 degrees of the macula of DR patients.

Secondary

MeasureTime frameDescription
To evaluate the level of agreement between OCT images captured by NOTAL-OCT V3.0 and a by commercial OCTLess then an hourThe measurement of fluid as identified by an eye-care professional, in the central 10 degrees of the macula of DR patients.
To evaluate repeatabilityLess then an hourTo evaluate the repeatability of the detection of fluid in images captured by NOTAL-OCT V3.0 in the central 10 degrees of the macula of AMD and DR patients.
To evaluate the level of agreement between NOTAL-OCT V3.0 and a commercial OCT in the presence of fluidLess then an hourThe measurement of fluid as identified by an eye-care professional, in the central 10 degrees of the macula.

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026